Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months

Ponticelli, D.; Antonazzo, Ippazio Cosimo; Caci, Grazia; Vitale, A.; Ragione, G. Della; Romano, Maria L; Borrelli, Mario; Schiavone, Beniamino; Polosa, Riccardo; Ferrara, Pietro

doi:10.1093/jtm/taab173

Cited by 27 publications

(43 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Complete cohort characteristics and study methods have been described in previous articles. 1 , 2 In brief, HCWs who were administered two doses of the BNT162b2 mRNA vaccine, 21 days apart, between December 2020 and January 2021, underwent multiple quantitative serology tests to identify SARS-CoV-2 S-RBD-specific IgG. Participant HCWs also responded to questions about their smoking status (i.e.…”

Section: Methodsmentioning

confidence: 99%

“…Monitoring the level and time trend of the humoral response to COVID-19 vaccines represents an essential tool in the study of immunological response and enables a greater understanding of the protection offered by the vaccination during the SARS-CoV-2 pandemic. 1 This study presents a subanalysis of the VASCO project (‘Monitoraggio della risposta al V accino A nti- S ARS-CoV-2/ CO VID-19 negli operatori sanitari del Pineta Grande Hospital’), an ongoing longitudinal study that investigates the effectiveness, immunogenicity, and safety of the BNT162b2 mRNA COVID-19 vaccine (also known as the BioNTech-Pfizer COVID-19 vaccine) in a sample of healthcare workers (HCWs). 1 , 2 The study includes an analysis of the dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine at monthly intervals over a period of 6 months.…”

Section: Introductionmentioning

confidence: 99%

“… 1 This study presents a subanalysis of the VASCO project (‘Monitoraggio della risposta al V accino A nti- S ARS-CoV-2/ CO VID-19 negli operatori sanitari del Pineta Grande Hospital’), an ongoing longitudinal study that investigates the effectiveness, immunogenicity, and safety of the BNT162b2 mRNA COVID-19 vaccine (also known as the BioNTech-Pfizer COVID-19 vaccine) in a sample of healthcare workers (HCWs). 1 , 2 The study includes an analysis of the dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine at monthly intervals over a period of 6 months. A decrease in vaccine-induced anti-S-RBD immunoglobulin G (IgG) antibodies was seen at the second month (i.e.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Does smoking have an impact on the immunological response to COVID-19 vaccines? Evidence from the VASCO study and need for further studies

et al. 2022

Self Cite

View full text Add to dashboard Cite

Objectives The aim of this study was to investigate the possible impact of smoking on the humoral response to the BNT162b2 mRNA COVID-19 vaccine (also known as the BioNTech-Pfizer COVID-19 vaccine). Study design A longitudinal sero-epidemiological study was conducted in sample of Italian healthcare workers (HCWs). Methods HCWs who were administered two doses of the BNT162b2 mRNA vaccine, 21 days apart, between December 2020 and January 2021, were invited to undergo multiple serology tests to identify SARS-CoV-2 S-RBD-specific immunoglobulin G (IgG) antibodies. Participants also responded to questions about their smoking status (i.e. current smokers vs non-smokers) in a survey. Results Sixty days after the completion of the vaccination cycle, serological analyses showed a difference in vaccine-induced IgG titre between current smokers and non-smokers, with median antibody titres of 211.80 AU/mL (interquartile range [IQR] 149.80–465.50) and 487.50 AU/mL (IQR 308.45–791.65) [ P -value = 0.002], respectively. This significant difference in vaccine-induced IgG titres between current smokers and non-smokers remained after adjusting for age, sex, and previous infection with SARS-CoV-2. Conclusions This study observed that vaccine-induced antibody titres decrease faster among current smokers than non-smokers. Further research to investigate the impact of smoking on the immunological response to COVID-19 and non-COVID-19 vaccines is required.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Does smoking have an impact on the immunological response to COVID-19 vaccines? Evidence from the VASCO study and need for further studies

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Serraino and colleagues [ 1 ] report a greater boosting of antibody concentrations when vaccines were administered 2 months or more after SARS-CoV-2 diagnosis, confirming the observations about the role of prior SARS-CoV-2 infection in immune priming [ 2 , 3 ].…”

mentioning

confidence: 62%

“…Collectively, the work by Serraino and colleagues, together with our findings [ 2 , 3 ], suggest how important it is to use data derived from analysis of real-world evidence to understand how COVID-19 vaccines are helping control the pandemic and to tailor the most appropriate population-level interventions to protect against COVID-19.…”

mentioning

confidence: 92%

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up—Reply

2022

Self Cite

View full text Add to dashboard Cite

Characterization of the significant decline in humoral immune response six months post‐SARS‐CoV‐2 mRNA vaccination: A systematic review

Notarte

Guerrero-Arguero

Velasco

et al. 2022

Journal of Medical Virology

112

View full text Add to dashboard Cite

Accumulating evidence shows a progressive decline in the efficacy of coronavirus disease 2019 (COVID‐19) (severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]) messenger RNA (mRNA) vaccines such as Pfizer‐BioNTech (mRNA BNT161b2) and Moderna (mRNA‐1273) in preventing breakthrough infections due to diminishing humoral immunity over time. Thus, this review characterizes the kinetics of anti‐SARS‐CoV‐2 antibodies after the second dose of a primary cycle of COVID‐19 mRNA vaccination. A systematic search of the literature was performed and a total of 18 articles ( N = 15 980 participants) were identified and reviewed. The percent difference of means of reported antibody titers was then calculated to determine the decline in humoral response after the peak levels postvaccination. Findings revealed that the peak humoral response was reached at 21–28 days after the second dose, after which serum levels progressively diminished at 4–6‐month postvaccination. Additionally, results showed that regardless of age, sex, serostatus, and presence of comorbidities, longitudinal data reporting antibody measurement exhibited a decline of both anti‐receptor binding domain immunoglobulin G (IgG) and anti‐spike IgG, ranging from 94% to 95% at 90–180 days and 55%–85% at 140–160 days, respectively, after the peak antibody response. This suggests that the rate of antibody decline may be independent of patient‐related factors and peak antibody titers but mainly a function of time and antibody class/molecular target. Hence, this study highlights the necessity of more efficient vaccination strategies to provide booster administration in attenuating the effects of waning immunity, especially in the appearance of new variants of concerns.

show abstract

Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine after 6 months

Cited by 27 publications

References 7 publications

Does smoking have an impact on the immunological response to COVID-19 vaccines? Evidence from the VASCO study and need for further studies

Does smoking have an impact on the immunological response to COVID-19 vaccines? Evidence from the VASCO study and need for further studies

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up—Reply

Characterization of the significant decline in humoral immune response six months post‐SARS‐CoV‐2 mRNA vaccination: A systematic review

Contact Info

Product

Resources

About